AstraZeneca reports positive results from endometrial cancer therapy trial
The study’s dual primary endpoint was progression-free survival.

The study’s dual primary endpoint was progression-free survival.
The trial will assess the pharmacokinetics, safety, and tolerability of S-892216 in healthy adults.
The global pharmaceutical industry experienced a 10% rise in new job postings related to social responsibility in Q3 2022 compared…
It’s a match! Connecting patients to clinical trials with AI
Netramark unveils ChatGPT-based clinical trial de-risking technology
Navigating uncertainty: How Covid-19 has changed the CRO and sponsor dynamic
Novavax employs AI-based dose selection for Covid-influenza vaccine trials